Isocitric dehydrogenase: an actionable genetic alteration in cholangiocarcinoma (ID 4671)
The scientific rationale for mIDH1 inhibition (ID 4672)
Clinical evaluation of mIDH1 inhibition (ID 4673)
Discussion on the clinical value of mIDH inhibition (ID 4674)
Identifying patients with mIDH1: how and when to do molecular testing (ID 4675)
What does all this mean for a patient with cholangiocarcinoma (ID 4676)
Q&A + Discussion (ID 4677)
